StockNews.AI
AZN
StockNews.AI
216 days

AstraZeneca PLC Sued for Securities Law Violations - Contact The Gross Law Firm Before February 21, 2025 to Discuss Your Rights – AZN

1. AstraZeneca faces legal action over alleged fraud in China. 2. Detention of China President indicates serious legal exposure. 3. Shareholders from Feb 23, 2022 to Dec 17, 2024 may join class action. 4. Class action claims misleading statements inflated stock value. 5. Deadline to register as a lead plaintiff is February 21, 2025.

4m saved
Insight
Article

FAQ

Why Very Bearish?

Legal issues and fraud allegations can significantly lower investor confidence, affecting stock price. Previous cases show that legal troubles often lead to stock declines.

How important is it?

The allegations of fraud and legal risks directly relate to AZN's business operations and stock valuation. Past examples indicate significant market reactions to legal challenges.

Why Short Term?

Immediate concerns regarding legal exposure will likely impact AZN's short-term performance. Similar past legal issues typically show rapid market reactions.

Related Companies

AZN
NEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of AstraZeneca PLC (NASDAQ: AZN). Shareholders who purchased shares of AZN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/astrazeneca-plc-loss-submission-form-2/?id=122775&from=3 CLASS PERIOD: February 23, 2022 to December 17, 2024 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) AstraZeneca engaged in insurance fraud in China; (2) as a result, AstraZeneca faced heightened legal exposure in China, which eventually resulted in the AstraZeneca China President being detained by Chinese law enforcement authorities; (3) as a result, AstraZeneca understated its legal risks; (4) the foregoing, once revealed, could materially harm AstraZeneca’s business activities in China; and (5) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. DEADLINE: February 21, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/astrazeneca-plc-loss-submission-form-2/?id=122775&from=3 NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of AZN during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is February 21, 2025. There is no cost or obligation to you to participate in this case. WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:The Gross Law Firm15 West 38th Street, 12th floorNew York, NY, 10018Email: dg@securitiesclasslaw.comPhone: (646) 453-8903

Related News